Nephros (NEPH) Liabilities and Shareholders Equity (2010 - 2026)

Nephros' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $13.8 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 17.12% year-over-year to $13.8 million in Q1 2026; TTM through Mar 2026 was $52.9 million, a 19.0% increase from a year earlier, with the FY2025 full-year figure at $13.6 million, up 21.69% from the prior year.
• Liabilities and Shareholders Equity rose to $13.8 million in Q1 2026 per NEPH's latest filing, from $13.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $15.5 million in Q1 2022 and bottomed at $10.4 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $11.4 million (2024), against an average of $12.1 million.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 37.68% in 2022 and advanced 27.55% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $11.0 million in 2022, then climbed by 7.84% to $11.9 million in 2023, then retreated by 5.49% to $11.2 million in 2024, then advanced by 21.69% to $13.6 million in 2025, then climbed by 1.12% to $13.8 million in 2026.
• Per Business Quant, the three latest NEPH Liabilities and Shareholders Equity figures stand at $13.8 million (Q1 2026), $13.6 million (Q4 2025), and $13.2 million (Q3 2025).